CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05520775
NCT05520775Phase 2Completed
CompareCT.gov

Human Laboratory Screening of Semaglutide for Alcohol Use Disorder

University of North Carolina, Chapel Hill·interventional·Posted Aug 30, 2022·Updated Apr 2, 2025

In Brief

A Phase 2 clinical trial evaluating Semaglutide and Sham/placebo for Alcohol Use Disorder and Cigarette Smoking. Completed, enrolled 48 participants across 1 site.

Detailed Summary

This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder, Cigarette Smoking
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedAug 30, 2022
Enrollment StartSep 2, 2022
Primary CompletionApr 12, 2024
Study CompletionApr 19, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.8 years ago

Interventions

Semaglutidedrug

Semaglutide (subcutaneous)

Sham/placebodrug

Sham subcutaneous injection